How to Progress Safe and Effective Cell Therapies for Clinical Use!
News Jul 19, 2011
Sistemic believe cell characterization is an essential element in progressing safe and effective cell therapies for mainstream clinical use.
They offer unique miRNA analytical services that provide reliable and cost-effective, characterization and QC tools that are applicable to all cell systems.
Toward this end, Dr Vincent O’Brien (Chief Scientific Officer) and Dr Verna McErlane (Director of Commercial Operations, International) will present data supporting the utility of miRNA in the provision of superior cell characterization and QC methods at the forthcoming Stem Cells Europe conference (20-21 July 2011, Edinburgh).
Dr. Vincent O’Brien will present a poster entitled; ‘A novel microRNA-based stem cell characterization and monitoring tool’, and Verna McErlane will join: Marilyn Robertson, SSCN; Aidan Courtney, Roslin Cells; Dr. David Hay, Fibromed; and, Michael Leek, Immunosolv, at the Scottish Stem Cell Network (SSCN) Panel showcase, “Progress to Therapy and Market” on Wednesday 20 July at 5pm.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE